How Work Gets Done
Parallel Bio announced in June 2026 that it was centering U.S. operations at a single Brisbane, California headquarters, bringing computational and biological functions together in one location. "Bringing our team together in the Bay Area allows us to move faster and integrate our computational and biology work more tightly," co-founder Robert DiFazio said in the release.
DiFazio and Juliana Hilliard founded the company in 2021 in San Francisco. At the time, DiFazio directed an interdisciplinary institute of over 150 faculty studying human immunology at Stanford University, and Hilliard worked at Herophilus (formerly System1), adapting brain organoid technology for high-throughput drug discovery.
The current headcount sits at roughly nine salaried roles, per Zero G Talent's board data, with a median salary band of $165,000. Recent postings show a cluster of senior biology and platform engineering roles in San Francisco alongside a Corporate Program Manager and IT Operations Lead based in New York or remote.
The platform — an organoid-based "immune system in a dish" that has tested 50-plus compounds across 170-plus patient backgrounds with 87 percent concordance to human outcomes — demands tight iteration cycles. The company states a 10x speed claim over traditional discovery on its homepage and in investor materials.
"We're excited to grow our team here and continue advancing human-first drug discovery with support from some of the world's leading experts in immunology, AI, and biotech," Hilliard said.
The Mission and the Machine
Parallel Bio's stated mission is to solve the real reason drugs fail. The founders frame the problem as a category error: pharma has spent 90 years optimizing for animal biology, then gambling billions that the results translate to humans. The numbers they cite are unsparing: $2.6 billion and 12.5 years per approved drug, a 97.3 percent clinical failure rate, and annual price increases of roughly 10 percent while major diseases go untreated.
That framing sets the decision filter for internal priorities. As the company's blog states: "If you want to change an entire industry, you have to be in the room with the right people. Today, the World Economic Forum (WEF) named Parallel Bio a 2026 Technology Pioneer."
The operating principle is human-first prediction at population scale. The platform is built on a biobank of 170-plus donors spanning ages, sexes, ethnicities, disease states, and genetic backgrounds, providing more diversity than many clinical trials achieve. The team's language shifts from "Does this drug work in genetically identical male mice?" to "How does this drug perform across the actual human population?"
That shift drives technical choices: scalable human immune organoids, perturbable systems, closed-loop automation that generates compounding proprietary data. The flywheel metaphor appears repeatedly in founder communications: each experiment feeds the atlas, the atlas improves the next experiment, and the data asset grows in value non-linearly.
Speed and cost compression are explicit targets. The company publishes 10x faster and 1,000x lower cost as benchmarks, alongside 87 percent concordance with human outcomes and zero animals used. These figures appear on the homepage and function as internal OKRs as much as external claims.
The Co-CEO structure (Hilliard and DiFazio) reinforces shared accountability. Collaboration with three Fortune 500 companies and a Phase 1 trial informed by Parallel data signal that the value system extends beyond the lab. The knowledge center blog, launched in 2026, positions transparency as a recruiting and credibility lever: "We're excited to share what we're working on, why it's important, and how we're thinking of solving some of the world's biggest challenges in human health."
The Hiring Bar
Parallel Bio runs its hiring the way it runs its science: lean, founder-led, and allergic to process for process's sake. At fewer than 50 people (some counts put the team at 20), there is no recruiting function. Your application lands in the inbox of a founder who is also running sales, product, and payroll. The obstacle isn't an applicant-tracking system; it's being seen at all. Cold outreach outperforms the form consistently, and a recycled CV gets rejected fast. They notice.
The screen filters for two things: relevant experience and the ability to operate autonomously. "Relevant experience and culture fit is the priority," the company's hiring guidance states. "Show you can work autonomously — that matters more than algorithms at <50 people." The careers page frames it more aspirationally: "We're building a diverse, interdisciplinary team of dreamers and doers. We're looking for fellow visionaries hungry for real impact in reimagining every facet of how we cure disease."
First-party board data from Zero G Talent shows what the bar buys in compensation. The salary band across nine salaried roles runs $63k–$244k with a $165k median. Leadership roles command a premium:
| Role | Location | Salary Band (USD/year) |
|---|---|---|
| Head of Biology | San Francisco, CA | $280,000–$305,000 |
| Head of Platform Bioengineering & Assay Development | San Francisco, CA | $203,000–$229,000 |
| Corporate Program Manager, Firmwide | New York, NY / Remote (NY) | $155,000–$172,000 |
| IT/OT Specialist | San Francisco, CA | $145,000–$165,000 |
| IT Operations Lead | New York, NY | $147,000–$154,000 |
Roles at sub-50-person drug discovery companies typically draw 50–100 applicants in the first two weeks. Applying inside 72 hours of a posting going live is the single biggest lever a candidate controls. Most applications get ghosted; a day-five follow-up can double the response rate.
The Indeed reviews for "Parallel" describe a cannabis cultivation operator with greenhouses in Pittsburgh (job titles include Cultivation Technician, Harvest Technician, Teacher, Server) and are unrelated to Parallel Bio. Parallel Bio has since exited Y Combinator, signed eight pharma partners, and shifted toward in-house drug development. The current hiring guidance emphasizes autonomy and relevance.
Who thrives: scientists and engineers who have operated in small, high-trust teams where the distance between hypothesis and experiment is short. The Head of Biology and Head of Platform Bioengineering roles signal that the company expects its technical leads to own workstreams end-to-end. The Corporate Program Manager role, sitting in New York with a remote option, suggests the company also values operators who can translate scientific velocity into milestone tracking. The IT/OT Specialist and IT Operations Lead postings indicate a need for infrastructure people who understand both lab instrumentation and cloud orchestration.
Who burns out: anyone who needs a runbook before they act. The median salary of $165k across nine roles is the clearest proxy for the experience floor. If you have not yet owned a workstream end-to-end — assay development from target validation to screening cascade, or a platform build from microfluidic prototype to GMP-ready run — the environment will not teach you; it will expose the gap.
The Brisbane headquarters sits in the Bay Area, a single building where the organoid farm and the compute cluster share a hallway. That proximity is the culture made physical: no timezone lag, no excuse for the iteration cycle to stretch beyond a day. The company bets that the best scientists and engineers will choose that density over the comfort of a managed process. So far, the bet is holding — but the next hire will test it again.
Working in frontier tech? Zero G Talent tracks the openings: see every open Parallel Bio role, browse frontier tech jobs, the companies hiring, and the people building the field.